加藤 俊介 かとう しゅんすけ 先生

来歴等

略歴

1992年 東北大学 医学部 卒業
1996年 東北大学大学院 医学研究科 博士課程 修了 医学博士取得
2000年 東北大学加齢医学研究所附属病院 助手（化学療法科）
2007年 東北大学病院 講師
2009年 東北大学 加齢医学研究所 癌化学療法研究分野 准教授
2013年 順天堂大学大学院 医学研究科臨床腫瘍学 教授

論文

• 1. Tumour-Agnostic Therapy for Pancreatic Cancer and Biliary Tract Cancer. Diagnostics (Basel) 11(2).

  Kato, S. (2021).

• 2. A novel diagnostic system to evaluate epidermal growth factor receptor impact as a prognostic and therapeutic indicator for lung adenocarcinoma. Sci Rep 10(1): 6214.

  Takakuwa, K., et al. (2020).

• 3. Japan society of clinical oncology/Japanese society of medical oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors, cooperated by the Japanese society of pediatric hematology/oncology. Int J Clin Oncol 25(3): 403-417.

  Naito, Y., et al. (2020).

• 4. Multicenter experience with large panel next-generation sequencing in patients with advanced solid cancers in Japan. Jpn J Clin Oncol 49(2): 174-182.

  Kato, S., et al. (2019).

• 5. Molecular and clinical features of the TP53 signature gene expression profile in early-stage breast cancer. Oncotarget 9(18): 14193-14206.

  Yamaguchi, S., et al. (2018).

• 6. Diagnosis and treatment of bone metastasis: comprehensive guideline of the Japanese Society of Medical Oncology, Japanese Orthopedic Association, Japanese Urological Association, and Japanese Society for Radiation Oncology. ESMO Open 1(2): e000037.

  Shibata, H., et al. (2016).

• 7. High throughput RNAi screening identifies ID1 as a synthetic sick/lethal gene interacting with the common TP53 mutation R175H. Oncol Rep 31(3): 1043-1050.

  Imai, H., et al. (2014).

• 8. Safety verification trials of mFOLFIRI and sequential IRIS + bevacizumab as first- or second-line therapies for metastatic colorectal cancer in Japanese patients. Oncology 83(2): 101-107.

  Kato, S., et al. (2012).

• 9. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28(6): 622-629.

  Petitjean, A., et al. (2007).

• 10. The UMD TP53 database and website: update and revisions. Hum Mutat 27(1): 14-20.

  Hamroun, D., et al. (2006).

• 11. Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study. Ann Oncol 17(5): 842-847.

  Iacopetta, B., et al. (2006).

• 12. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res 12(4): 1157-1167.

  Olivier, M., et al. (2006).

• 13. Computational approaches for predicting the biological effect of p53 missense mutations: a comparison of three sequence analysis based methods. Nucleic Acids Res 34(5): 1317-1325.

  Mathe, E., et al. (2006).

• 14. Meta-analysis of the p53 mutation database for mutant p53 biological activity reveals a methodologic bias in mutation detection. Clin Cancer Res 12(1): 62-69.

  Soussi, T., et al. (2006).

• 15. Predicting the transactivation activity of p53 missense mutants using a four-body potential score derived from Delaunay tessellations. Hum Mutat 27(2): 163-172.

  Mathe, E., et al. (2006).

• 16. Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations. Hum Mutat 25(1): 6-17.

  Soussi, T., et al. (2005).

• 17. Lack of correlation between p53-dependent transcriptional activity and the ability to induce apoptosis among 179 mutant p53s. Cancer Res 65(6): 2108-2114.

  Kakudo, Y., et al. (2005).

• 18. The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library. Oncogene 24(46): 6976-6981.

  Kawaguchi, T., et al. (2005).

• 19. Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library. J Biol Chem 279(1): 348-355.

  Shiraishi, K., et al. (2004).

• 20. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci U S A 100(14): 8424-8429.

  Kato, S., et al. (2003).

• 21. Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay. Cancer Res 60(12): 3147-3151.

  Han, S. Y., et al. (2000).

• 22. The transcriptional activities of p53 and its homologue p51/p63: similarities and differences. Cancer Res 59(12): 2781-2786.

  Shimada, A., et al. (1999).

• 23. Mutational analysis of p51A/TAp63gamma, a p53 homolog, in non-small cell lung cancer and breast cancer. Oncogene 18(25): 3761-3765.

  Sunahara, M., et al. (1999).

• 24. Effects of p51/p63 missense mutations on transcriptional activities of p53 downstream gene promoters. Cancer Res 59(23): 5908-5911.

  Kato, S., et al. (1999).

• 25. Differentiation-dependent enhanced expression of protein phosphatase 2Cbeta in germ cells of mouse seminiferous tubules. FEBS Lett 396(2-3): 293-297.

  Kato, S., et al. (1996).